Literature DB >> 28199152

Can Radiologists Predict the Presence of Ductal Carcinoma In Situ and Invasive Breast Cancer?

Shadi Aminololama-Shakeri1, Chris I Flowers2,3, Christine E McLaren4, Dorota J Wisner5,6, Jade de Guzman7, Joan E Campbell8, Lawrence W Bassett9, Haydee Ojeda-Fournier7, Karen Gerlach8,10, Jonathan Hargreaves1, Sarah L Elson5,11, Hanna Retallack5, Bonnie N Joe5, Stephen A Feig8, Colin J Wells9.   

Abstract

OBJECTIVE: We hypothesize that radiologists' estimated percentage likelihood assessments for the presence of ductal carcinoma in situ (DCIS) and invasive cancer may predict histologic outcomes.
MATERIALS AND METHODS: Two hundred fifty cases categorized as BI-RADS category 4 or 5 at four University of California Medical Centers were retrospectively reviewed by 10 academic radiologists with a range of 1-39 years in practice. Readers assigned BI-RADS category (1, 2, 3, 4a, 4b, 4c, or 5), estimated percentage likelihood of DCIS or invasive cancer (0-100%), and confidence rating (1 = low, 5 = high) after reviewing screening and diagnostic mammograms and ultrasound images. ROC curves were generated.
RESULTS: Sixty-two percent (156/250) of lesions were benign and 38% (94/250) were malignant. There were 26 (10%) DCIS, 20 (8%) invasive cancers, and 48 (19%) cases of DCIS and invasive cancer. AUC values were 0.830-0.907 for invasive cancer and 0.731-0.837 for DCIS alone. Sensitivity of 82% (56/68), specificity of 84% (153/182), positive predictive value (PPV) of 66% (56/85), negative predictive value (NPV) of 93% (153/165), and accuracy of 84% ([56 + 153]/250) were calculated using an estimated percentage likelihood of 20% or higher as the prediction threshold for invasive cancer for the radiologist with the highest AUC (0.907; 95% CI, 0.864-0.951). Every 20% increase in the estimated percentage likelihood of invasive cancer increased the odds of invasive cancer by approximately two times (odds ratio, 2.4). For DCIS, using a threshold of 40% or higher, sensitivity of 81% (21/26), specificity of 79% (178/224), PPV of 31% (21/67), NPV of 97% (178/183), and accuracy of 80% ([21 + 178]/250) were calculated. Similarly, these values were calculated at thresholds of 2% or higher (BI-RADS category 4) and 95% or higher (BI-RADS category 5) to predict the presence of malignancy.
CONCLUSION: Using likelihood estimates, radiologists may predict the presence of invasive cancer with fairly high accuracy. Radiologist-assigned estimated percentage likelihood can predict the presence of DCIS, albeit with lower accuracy than that for invasive cancer.

Entities:  

Keywords:  BI-RADS; ROC curves; breast cancer; digital mammography; ductal carcinoma in situ; invasive breast cancer; kappa coefficients

Mesh:

Year:  2017        PMID: 28199152      PMCID: PMC7777562          DOI: 10.2214/AJR.16.16073

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  10 in total

Review 1.  Percutaneous image-guided core breast biopsy.

Authors:  Laura Liberman
Journal:  Radiol Clin North Am       Date:  2002-05       Impact factor: 2.303

2.  The positive predictive value of BI-RADS microcalcification descriptors and final assessment categories.

Authors:  Chris K Bent; Lawrence W Bassett; Carl J D'Orsi; James W Sayre
Journal:  AJR Am J Roentgenol       Date:  2010-05       Impact factor: 3.959

3.  BI-RADS lexicon for US and mammography: interobserver variability and positive predictive value.

Authors:  Elizabeth Lazarus; Martha B Mainiero; Barbara Schepps; Susan L Koelliker; Linda S Livingston
Journal:  Radiology       Date:  2006-03-28       Impact factor: 11.105

4.  Observer variability in screen-film mammography versus full-field digital mammography with soft-copy reading.

Authors:  Per Skaane; Felix Diekmann; Corinne Balleyguier; Susanne Diekmann; Jean-Charles Piguet; Kari Young; Michael Abdelnoor; Loren Niklason
Journal:  Eur Radiol       Date:  2008-02-27       Impact factor: 5.315

5.  Potential usefulness of similar images in the differential diagnosis of clustered microcalcifications on mammograms.

Authors:  Ryohei Nakayama; Hiroyuki Abe; Junji Shiraishi; Kunio Doi
Journal:  Radiology       Date:  2009-09-29       Impact factor: 11.105

6.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

7.  Variability in radiologists' interpretations of mammograms.

Authors:  J G Elmore; C K Wells; C H Lee; D H Howard; A R Feinstein
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

8.  Positive predictive value of specific mammographic findings according to reader and patient variables.

Authors:  Aruna Venkatesan; Philip Chu; Karla Kerlikowske; Edward A Sickles; Rebecca Smith-Bindman
Journal:  Radiology       Date:  2009-01-21       Impact factor: 11.105

9.  Predicting invasive breast cancer versus DCIS in different age groups.

Authors:  Mehmet U S Ayvaci; Oguzhan Alagoz; Jagpreet Chhatwal; Alejandro Munoz del Rio; Edward A Sickles; Houssam Nassif; Karla Kerlikowske; Elizabeth S Burnside
Journal:  BMC Cancer       Date:  2014-08-11       Impact factor: 4.430

10.  Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention.

Authors:  Chris I Flowers; Cristina O'Donoghue; Dan Moore; Adeline Goss; Danny Kim; June-Ho Kim; Sjoerd G Elias; Julia Fridland; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2013-06-14       Impact factor: 4.872

  10 in total
  2 in total

1.  MRI ductography of contrast agent distribution and leakage in normal mouse mammary ducts and ducts with in situ cancer.

Authors:  Erica Markiewicz; Xiaobing Fan; Devkumar Mustafi; Marta Zamora; Suzanne D Conzen; Gregory S Karczmar
Journal:  Magn Reson Imaging       Date:  2017-03-30       Impact factor: 2.546

2.  Contrast-enhanced spectral mammography: A potential exclusion diagnosis modality in dense breast patients.

Authors:  Yun Qin; Ying Liu; Xueqin Zhang; Shuang Zhao; Huanhuan Zhong; Juan Huang; Jianqun Yu
Journal:  Cancer Med       Date:  2020-02-19       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.